At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ICCM IceCure Medical Ltd.
Post-Mkt 04-13 17:18:59 EDT
0.3374
+0.0141
+4.36%
盘后0.3301
-0.0073-2.16%
17:01 EDT
High0.3396Low0.3067Vol362.06K
Open0.3300D1 Closing0.3233Amplitude10.18%
Mkt Cap27.39MTradable Cap17.99MTotal Shares81.18M
T/O117.37KT/O Rate0.68%Tradable Shares53.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

IceCure Medical files to sell 16M ordinary share for holders
TIPRANKS  ·  04-02
IceCure Medical files to sell 16M ordinary share for holders
IceCure prices $4.0 million registered direct offering at $0.50 per share; adds Series B and C warrants at $0.55 exercise price
Reuters  ·  03-26
IceCure prices $4.0 million registered direct offering at $0.50 per share; adds Series B and C warrants at $0.55 exercise price
Icecure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
THOMSON REUTERS  ·  03-26
Icecure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
IceCure Medical files Form 3 initial beneficial ownership statement; director Ron Mayron reports 296,631 ordinary shares
Reuters  ·  03-26
IceCure Medical files Form 3 initial beneficial ownership statement; director Ron Mayron reports 296,631 ordinary shares
IceCure Medical; CEO and director Eyal Shamir files initial beneficial ownership statement```
Reuters  ·  03-26
IceCure Medical; CEO and director Eyal Shamir files initial beneficial ownership statement```
IceCure Medical Posts Strong 5-Year Kidney Cancer Cryoablation Data From ICESECRET Trial
TIPRANKS  ·  03-25
IceCure Medical Posts Strong 5-Year Kidney Cancer Cryoablation Data From ICESECRET Trial
IceCure Medical reports results from clinical trial of ProSense for SRMs
TIPRANKS  ·  03-25
IceCure Medical reports results from clinical trial of ProSense for SRMs
IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm
Reuters  ·  03-25
IceCure reports ICESECRET ProSense kidney cancer trial; recurrence-free rate rises to 89.4% for tumors ≤3 cm
Icecure Medical Ltd - 89.4% Recurrence-Free Rate for Tumors ≤3 Cm, 83.9% for General Population at 4 Years
THOMSON REUTERS  ·  03-25
Icecure Medical Ltd - 89.4% Recurrence-Free Rate for Tumors ≤3 Cm, 83.9% for General Population at 4 Years
Icecure Reports Positive 5-Year Top-Line Results From Icesecret Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
THOMSON REUTERS  ·  03-25
Icecure Reports Positive 5-Year Top-Line Results From Icesecret Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
IceCure Medical Names New CFO and Plans Key Leadership Changes Amid ProSense® Growth
TIPRANKS  ·  03-24
IceCure Medical Names New CFO and Plans Key Leadership Changes Amid ProSense® Growth
IceCure names Meir Peleg CFO effective May 17, 2026
Reuters  ·  03-24
IceCure names Meir Peleg CFO effective May 17, 2026
BRIEF-Icecure Appoints Meir Peleg As Chief Financial Officer
Reuters  ·  03-24
BRIEF-Icecure Appoints Meir Peleg As Chief Financial Officer
Icecure Appoints Meir Peleg as Chief Financial Officer
THOMSON REUTERS  ·  03-24
Icecure Appoints Meir Peleg as Chief Financial Officer
Press Release: IceCure Appoints Meir Peleg as Chief Financial Officer
Dow Jones  ·  03-24
Press Release: IceCure Appoints Meir Peleg as Chief Financial Officer
Icecure Medical Rides FDA, ASBRS Wins to Growth
TIPRANKS  ·  03-18
Icecure Medical Rides FDA, ASBRS Wins to Growth
IceCure Medical Director Li Haixiang Resigns Effective March 17, 2026
Reuters  ·  03-18
IceCure Medical Director Li Haixiang Resigns Effective March 17, 2026
IceCure Medical reports FY25 EPS 24c vs 30c last year
TIPRANKS  ·  03-17
IceCure Medical reports FY25 EPS 24c vs 30c last year
Israel's IceCure Medical 2025 gross margin falls to 36% on higher costs
Reuters  ·  03-17
Israel's IceCure Medical 2025 gross margin falls to 36% on higher costs
Icecure Medical Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.279M Miss $1.900M Estimate
Benzinga  ·  03-17
Icecure Medical Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.279M Miss $1.900M Estimate

Introduction

Company Name.
IceCure Medical Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Issue price:
--